PIMECROLIMUS for Psoriasis: Side Effects & Safety Data
Visibly Younger Skin in Weeks
Synevra Lift & Lock — Swiss peptide serum + nutrients. 60-day money-back guarantee.
There are 217 adverse event reports in the FDA FAERS database where PIMECROLIMUS was used for Psoriasis.
Most Reported Side Effects for PIMECROLIMUS
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Drug ineffective | 349 | 26.3% | 0 | 16 |
| Treatment failure | 139 | 10.5% | 0 | 0 |
| Psoriasis | 114 | 8.6% | 0 | 9 |
| Off label use | 113 | 8.5% | 0 | 2 |
| Pruritus | 94 | 7.1% | 0 | 4 |
| Erythema | 89 | 6.7% | 0 | 4 |
| Product use in unapproved indication | 86 | 6.5% | 1 | 1 |
| Rash | 82 | 6.2% | 0 | 4 |
| Application site pain | 72 | 5.4% | 0 | 2 |
| Therapeutic product effect incomplete | 65 | 4.9% | 0 | 3 |
| Condition aggravated | 59 | 4.5% | 0 | 5 |
| Drug ineffective for unapproved indication | 55 | 4.1% | 0 | 0 |
| Eczema | 52 | 3.9% | 0 | 5 |
| Skin exfoliation | 48 | 3.6% | 0 | 3 |
| Application site erythema | 41 | 3.1% | 0 | 1 |
Other Indications for PIMECROLIMUS
Product used for unknown indication (354)
Eczema (148)
Dermatitis atopic (103)
Dermatitis (55)
Rash (52)
Rosacea (46)
Product use in unapproved indication (40)
Pruritus (28)
Dermatitis contact (20)
Vitiligo (20)
Other Drugs Used for Psoriasis
APREMILAST (76,127)
SECUKINUMAB (58,471)
ADALIMUMAB (56,634)
RISANKIZUMAB-RZAA (40,890)
ETANERCEPT (30,483)
USTEKINUMAB (21,763)
IXEKIZUMAB (16,569)
GUSELKUMAB (11,736)
CERTOLIZUMAB PEGOL (8,179)
METHOTREXATE (6,628)